Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press60410.17650/1994-4098-2018-14-3-25-39MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИMain risk factors for breast cancer and proposals for its preventionОсновные риски развития рака молочной железы и предложения по его профилактикеPortnoyS. M.ПортнойС. М.
Russian Federation

Build. 7, 5 Lefortovskiy Val, Moscow 111116

111116 Москва, Лефортовский вал, 5, стр. 7

sportnoj@yahoo.comFrau Clinic, LLCООО «Фрау Клиник»1610201814325391510201815102018https://ojrs.abvpress.ru/ojrs/article/view/604

This systematic literature review aims to explore currently accepted risk factors for breast cancer, including reproductive status, overweight, radiation, breast radiological density, benign lesions, family history of breast cancer and mutations in breast cancer predisposition genes. The review also covers measures to prevent breast cancer.

Настоящий обзор литературы посвящен современному представлению о рисках развития рака молочной железы (РМЖ), к которым относятся особенности репродуктивной жизни женщины, избыточная масса тела, радиация, рентгенологическая плотность ткани молочной железы, наличие доброкачественных поражений, отягощенная наследственность по РМЖ, мутации генов предрасположенности к развитию РМЖ. Рассмотрены также меры профилактики развития РМЖ.

risk of breast cancerBRCA1BRCA2ATMBLMBRIP1CDH1CHEK2LKB1NBS1MLH1PALB2PTENRECQLTP53preventive mastectomyриск развития рака молочной железы, BRCA1, BRCA2, ATM, BLM, BRIP1, CDH1, CHEK2, LKB1, NBS1, MLH1, PALB2, PTEN, RECQL, TP53, профилактическая мастэктомия1. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦР» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦР» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].2. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146–51. PMID: 3965932. DOI: 10.1056/NEJM198501173120303.Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146–51. PMID: 3965932. DOI: 10.1056/NEJM198501173120303.3. Dupont W.D., Pad F.F., Hartmann W.H. et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71(4):1258–65. PMID: 8435803.Dupont W.D., Pad F.F., Hartmann W.H. et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71(4):1258–65. PMID: 8435803.4. Hartmann L.C., Sellers T.A., Frost M.H. et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353(3):229–37. PMID: 16034008. DOI: 10.1056/NEJMoa044383.Hartmann L.C., Sellers T.A., Frost M.H. et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353(3):229–37. PMID: 16034008. DOI: 10.1056/NEJMoa044383.5. Ford D., Easton D., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet 1998;62(3):676–89.Ford D., Easton D., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet 1998;62(3):676–89.6. Любченко Л.Н. Генодиагностика наследственной предрасположенности к раку молочной железы и разработка индивидуального прогнозирования развития, течения и профилактики заболевания. Автореф. дисс. … канд. мед. наук. М., 2002. 32 c. [Lyubchenko L.N. Molecular diagnostics of genetic predisposition to breast cancer, individual prognosis, and prevention. Summary of thesis … of candidate of medical sciences. Moscow, 2002. 32 p. (In Russ.)].Любченко Л.Н. Генодиагностика наследственной предрасположенности к раку молочной железы и разработка индивидуального прогнозирования развития, течения и профилактики заболевания. Автореф. дисс. … канд. мед. наук. М., 2002. 32 c. [Lyubchenko L.N. Molecular diagnostics of genetic predisposition to breast cancer, individual prognosis, and prevention. Summary of thesis … of candidate of medical sciences. Moscow, 2002. 32 p. (In Russ.)].7. Antoniou A., Pharoah P., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. PMID: 12677558. DOI: 10.1086/375033.Antoniou A., Pharoah P., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. PMID: 12677558. DOI: 10.1086/375033.8. Cybulski C., Wokołorczyk D., Jakubowska A. et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747–52. PMID: 21876083. DOI: 10.1200/JCO.2010.34.0778.Cybulski C., Wokołorczyk D., Jakubowska A. et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747–52. PMID: 21876083. DOI: 10.1200/JCO.2010.34.0778.9. Hwang S.J., Lozano G., Amos C.I., Strong L.C. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72(4):975–83. PMID: 12610779. DOI: 10.1086/374567.Hwang S.J., Lozano G., Amos C.I., Strong L.C. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72(4):975–83. PMID: 12610779. DOI: 10.1086/374567.10. Graeser M.K., Engel C., Rhiem K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27(35):5887–92. PMID: 19858402. DOI: 10.1200/JCO.2008.19.9430.Graeser M.K., Engel C., Rhiem K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27(35):5887–92. PMID: 19858402. DOI: 10.1200/JCO.2008.19.9430.11. Aloraifi F., McCartan D., McDevitt T. et al. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk casecontrol screening studies. Cancer Genetics 2015;208(9):455–63. PMID: 26250988. DOI: 10.1016/j.cancergen.2015.06.001.Aloraifi F., McCartan D., McDevitt T. et al. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk casecontrol screening studies. Cancer Genetics 2015;208(9):455–63. PMID: 26250988. DOI: 10.1016/j.cancergen.2015.06.001.12. Southey M.C., Goldgar D.E., Winqvist R. et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 2016;53(12):800–11. PMID: 27595995. DOI: 10.1136/jmedgenet-2016-103839.Southey M.C., Goldgar D.E., Winqvist R. et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 2016;53(12):800–11. PMID: 27595995. DOI: 10.1136/jmedgenet-2016-103839.13. Sokolenko A.P., Iyevleva A.G., Preobrazhenskaya E.V. et al. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer 2012;130(12):2867–73. PMID: 21815139. DOI: 10.1002/ijc.26342.Sokolenko A.P., Iyevleva A.G., Preobrazhenskaya E.V. et al. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer 2012;130(12):2867–73. PMID: 21815139. DOI: 10.1002/ijc.26342.14. Prokofyeva D., Bogdanova N., Dubrowinskaja N. et al. Nonsense mutation p. Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 2013;137(2):533–9. PMID: 23225144. DOI: 10.1007/s10549-012-2357-1.Prokofyeva D., Bogdanova N., Dubrowinskaja N. et al. Nonsense mutation p. Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 2013;137(2):533–9. PMID: 23225144. DOI: 10.1007/s10549-012-2357-1.15. Seal S., Thompson D., Renwick A. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38(11):1239–41. PMID: 17033622. DOI: 10.1038/ng1902.Seal S., Thompson D., Renwick A. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38(11):1239–41. PMID: 17033622. DOI: 10.1038/ng1902.16. Hansford S., Kaurah P., Li-Chang H. et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015;1(1):23–32. PMID: 26182300. DOI: 10.1001/jamaoncol.2014.168.Hansford S., Kaurah P., Li-Chang H. et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015;1(1):23–32. PMID: 26182300. DOI: 10.1001/jamaoncol.2014.168.17. Adank M.A., Jonker M.A., Kluijt I. et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet 2011;48(12):860–3. PMID: 22058428. DOI: 10.1136/jmedgenet-2011-100380.Adank M.A., Jonker M.A., Kluijt I. et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet 2011;48(12):860–3. PMID: 22058428. DOI: 10.1136/jmedgenet-2011-100380.18. Weischer M., Bojesen S.E., Ellervik C. et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26 000 patient cases and 27 000 controls. J Clin Oncol 2008;26(4):542–8. PMID: 18172190. DOI: 10.1200/JCO.2007.12.5922.Weischer M., Bojesen S.E., Ellervik C. et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26 000 patient cases and 27 000 controls. J Clin Oncol 2008;26(4):542–8. PMID: 18172190. DOI: 10.1200/JCO.2007.12.5922.19. Lim W., Hearle N., Shah B. et al. Further observations on LKB1/STK11 status and cancer risk in Peutz–Jeghers syndrome. Br J Cancer 2003;89(2):308–13. PMID: 12865922. DOI: 10.1038/sj.bjc.6601030.Lim W., Hearle N., Shah B. et al. Further observations on LKB1/STK11 status and cancer risk in Peutz–Jeghers syndrome. Br J Cancer 2003;89(2):308–13. PMID: 12865922. DOI: 10.1038/sj.bjc.6601030.20. Harkness E.F., Barrow E., Newton K. et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet 2015;52(8):553–6. PMID: 26101330. DOI: 10.1136/jmedgenet-2015-103216.Harkness E.F., Barrow E., Newton K. et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J Med Genet 2015;52(8):553–6. PMID: 26101330. DOI: 10.1136/jmedgenet-2015-103216.21. Antoniou A.C., Casadei S., Heikkinen T. et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371(6):497–506. PMID: 25337756. DOI: 10.1056/NEJMc1410673.Antoniou A.C., Casadei S., Heikkinen T. et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371(6):497–506. PMID: 25337756. DOI: 10.1056/NEJMc1410673.22. Tan M.H., Mester J.L., Ngeow J. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400–7. PMID: 22252256. DOI: 10.1158/1078-0432.CCR-11-2283.Tan M.H., Mester J.L., Ngeow J. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400–7. PMID: 22252256. DOI: 10.1158/1078-0432.CCR-11-2283.23. Ngeow J., Stanuch K., Mester J.L. et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014;32(17):1818–24. PMID: 24778394. DOI: 10.1200/JCO.2013.53.6656.Ngeow J., Stanuch K., Mester J.L. et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014;32(17):1818–24. PMID: 24778394. DOI: 10.1200/JCO.2013.53.6656.24. Sun J., Wang Y., Xia Y. et al. Mutations in RECQL gene are associated with predisposition to breast cancer. PLoS Genet 2015;11(5):e1005228. PMID: 25945795. DOI: 10.1371/journal.pgen.1005228.Sun J., Wang Y., Xia Y. et al. Mutations in RECQL gene are associated with predisposition to breast cancer. PLoS Genet 2015;11(5):e1005228. PMID: 25945795. DOI: 10.1371/journal.pgen.1005228.25. Cybulski C., Carrot-Zhang J., Kluźniak W. et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2015;47(6):643–6. PMID: 25915596. DOI: 10.1038/ng.3284.Cybulski C., Carrot-Zhang J., Kluźniak W. et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2015;47(6):643–6. PMID: 25915596. DOI: 10.1038/ng.3284.26. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13(11):1141–51. PMID: 23084519. DOI: 10.1016/S1470-2045(12)70425-4.Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13(11):1141–51. PMID: 23084519. DOI: 10.1016/S1470-2045(12)70425-4.27. Beral V., Bull D., Doll R. et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004;363(9414):1007–16. PMID: 15051280. DOI: 10.1016/S0140-6736(04)15835-2.Beral V., Bull D., Doll R. et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004;363(9414):1007–16. PMID: 15051280. DOI: 10.1016/S0140-6736(04)15835-2.28. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002;360(9328):187–95. PMID: 12133652. DOI: 10.1016/S0140-6736(02)09454-0.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002;360(9328):187–95. PMID: 12133652. DOI: 10.1016/S0140-6736(02)09454-0.29. Lambertini M., Santoro L., Del Mastro L. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews 2016;(49):65–76. PMID: 27529149. DOI: 10.1016/j.ctrv.2016.07.006.Lambertini M., Santoro L., Del Mastro L. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews 2016;(49):65–76. PMID: 27529149. DOI: 10.1016/j.ctrv.2016.07.006.30. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347(9017):1713–27. PMID: 8656904.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347(9017):1713–27. PMID: 8656904.31. Hunter D.J., Colditz G.A., Hankinson S.E. et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496–502. PMID: 20802021. DOI: 10.1158/1055-9965.EPI-10-0747.Hunter D.J., Colditz G.A., Hankinson S.E. et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496–502. PMID: 20802021. DOI: 10.1158/1055-9965.EPI-10-0747.32. Li L., Zhong Y., Zhang H. et al. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis. Mol Clin Oncol 2017;7(1):76–80. PMID: 28685080. DOI: 10.3892/mco.2017.1259.Li L., Zhong Y., Zhang H. et al. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis. Mol Clin Oncol 2017;7(1):76–80. PMID: 28685080. DOI: 10.3892/mco.2017.1259.33. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350(9084):1047–59. PMID: 10213546.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350(9084):1047–59. PMID: 10213546.34. Wang K., Li F., Chen L. et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget 2017;8(46):81109–24. PMID: 29113371. DOI: 10.18632/oncotarget.20154.Wang K., Li F., Chen L. et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget 2017;8(46):81109–24. PMID: 29113371. DOI: 10.18632/oncotarget.20154.35. Chen Y., Liu L., Zhou Q. et al. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response metaanalysis with 3 318 796 subjects from 31 cohort studies. BMC Public Health 2017;17(1):936–47. PMID: 29216920. DOI: 10.1186/s12889-017-4953-9.Chen Y., Liu L., Zhou Q. et al. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response metaanalysis with 3 318 796 subjects from 31 cohort studies. BMC Public Health 2017;17(1):936–47. PMID: 29216920. DOI: 10.1186/s12889-017-4953-9.36. Li C.I., Nishi N., McDougall J.A. et al. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. Cancer Res 2010;70(18):7187–98. PMID: 20843820. DOI: 10.1158/0008-5472.CAN-10-0276.Li C.I., Nishi N., McDougall J.A. et al. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. Cancer Res 2010;70(18):7187–98. PMID: 20843820. DOI: 10.1158/0008-5472.CAN-10-0276.37. Henderson T.O., Amsterdam A., Bhatia S. et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010;152(7):444–55. PMID: 20368650. DOI: 10.7326/0003-4819-152-7-201004060-00009.Henderson T.O., Amsterdam A., Bhatia S. et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010;152(7):444–55. PMID: 20368650. DOI: 10.7326/0003-4819-152-7-201004060-00009.38. Mulder R.L., Kremer L.C.M., Hudson M.M. et al. Recommendations for breast cancer surveillance for female childhood, adolescent and young adult cancer survivors treated with chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013;14(13):70303–6. PMID: 24275135. DOI: 10.1016/S1470-2045(13)70303-6.Mulder R.L., Kremer L.C.M., Hudson M.M. et al. Recommendations for breast cancer surveillance for female childhood, adolescent and young adult cancer survivors treated with chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013;14(13):70303–6. PMID: 24275135. DOI: 10.1016/S1470-2045(13)70303-6.39. Travis L.B., Hill D., Dores G.M. et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97(19):1428–37. PMID: 16204692. DOI: 10.1093/jnci/dji290.Travis L.B., Hill D., Dores G.M. et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97(19):1428–37. PMID: 16204692. DOI: 10.1093/jnci/dji290.40. Pettersson A., Graff R.E., Ursin G. et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2014;106(5):dju078. DOI: 10.1093/jnci/dju078.Pettersson A., Graff R.E., Ursin G. et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2014;106(5):dju078. DOI: 10.1093/jnci/dju078.41. Dyrstad S.W., Yan Y., Fowler A.M., Colditz G.A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 2015;149(3):569–75. PMID: 25636589. DOI: 10.1007/s10549-014-3254-6.Dyrstad S.W., Yan Y., Fowler A.M., Colditz G.A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 2015;149(3):569–75. PMID: 25636589. DOI: 10.1007/s10549-014-3254-6.42. Hartmann L.C., Degnim A.C., Santen R.J. et al. Atypical hyperplasia of the breast – risk assessment and management options. NEJM 2015;372(1):78–89. PMID: 25551530. DOI: 10.1056/NEJMsr1407164.Hartmann L.C., Degnim A.C., Santen R.J. et al. Atypical hyperplasia of the breast – risk assessment and management options. NEJM 2015;372(1):78–89. PMID: 25551530. DOI: 10.1056/NEJMsr1407164.43. Foote F.W., Stewart F.W. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941;17(4):491–5. PMID: 19970575. PMCID: PMC1965212.Foote F.W., Stewart F.W. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941;17(4):491–5. PMID: 19970575. PMCID: PMC1965212.44. Haagensen C.D., Lane N., Lattes R., Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42(2):737–69. PMID: 209887.Haagensen C.D., Lane N., Lattes R., Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42(2):737–69. PMID: 209887.45. Chuba P.J., Hamre M.R., Yap J. et al. Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology and end results data. J Clin Oncol 2005;23(24): 5534–41. PMID: 16110014. DOI: 10.1200/JCO.2005.04.038.Chuba P.J., Hamre M.R., Yap J. et al. Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology and end results data. J Clin Oncol 2005;23(24): 5534–41. PMID: 16110014. DOI: 10.1200/JCO.2005.04.038.46. King T.A., Pilewskie M., Muhsen S. et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol 2015;33(33):3945–52. PMID: 26371145. DOI: 10.1200/JCO.2015.61.4743.King T.A., Pilewskie M., Muhsen S. et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol 2015;33(33):3945–52. PMID: 26371145. DOI: 10.1200/JCO.2015.61.4743.47. Tehard B., Friedenreich C.M., Oppert J.M., Clavel-Chapelon F. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev 2006;15(1):57–64. PMID: 16434587. DOI: 10.1158/1055-9965.EPI-05-0603.Tehard B., Friedenreich C.M., Oppert J.M., Clavel-Chapelon F. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev 2006;15(1):57–64. PMID: 16434587. DOI: 10.1158/1055-9965.EPI-05-0603.48. Lahmann P.H., Friedenreich C., Schuit A.J. et al. Physical activity and breast cancer risk: the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2007;16(1):36–42. PMID: 17179488. DOI: 10.1158/1055-9965.EPI-06-0582.Lahmann P.H., Friedenreich C., Schuit A.J. et al. Physical activity and breast cancer risk: the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2007;16(1):36–42. PMID: 17179488. DOI: 10.1158/1055-9965.EPI-06-0582.49. Chlebowski R.T., Luo J., Anderson G.L. et al. Weight change in postmenopausal women and breast cancer risk in the women's health initiative observational study. SABCS 2017. Abstr. GS5-07.Chlebowski R.T., Luo J., Anderson G.L. et al. Weight change in postmenopausal women and breast cancer risk in the women's health initiative observational study. SABCS 2017. Abstr. GS5-07.50. The Breast Cancer Risk Assessment Tool. Available at: http://www.cancer.gov/bcrisktool/default.aspx.The Breast Cancer Risk Assessment Tool. Available at: http://www.cancer.gov/bcrisktool/default.aspx.51. Fisher B., Costantino J.P., Wickerham D.L. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97(22):1652–62. PMID: 16288118. DOI: 10.1093/jnci/dji372.Fisher B., Costantino J.P., Wickerham D.L. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97(22):1652–62. PMID: 16288118. DOI: 10.1093/jnci/dji372.52. Veronesi U., Maisonneuve P., Rotmensz N. et al. Tamoxifen for the prevention of breast cancer: late results of the italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007;99(9):727–37. PMID: 17470740. DOI: 10.1093/jnci/djk154.Veronesi U., Maisonneuve P., Rotmensz N. et al. Tamoxifen for the prevention of breast cancer: late results of the italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007;99(9):727–37. PMID: 17470740. DOI: 10.1093/jnci/djk154.53. Cuzick J., Sestak I., Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16(1):67–75. PMID: 25497694. DOI: 10.1016/S1470-2045(14)71171-4.Cuzick J., Sestak I., Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16(1):67–75. PMID: 25497694. DOI: 10.1016/S1470-2045(14)71171-4.54. Powles T.J., Ashley S., Tidy A. et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99(4):283–90. PMID: 17312305. DOI: 10.1093/jnci/djk050.Powles T.J., Ashley S., Tidy A. et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99(4):283–90. PMID: 17312305. DOI: 10.1093/jnci/djk050.55. Cuzick J., Sestak I., Bonanni B. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827–34. PMID: 23639488. DOI: 10.1016/S0140-6736(13)60140-3.Cuzick J., Sestak I., Bonanni B. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827–34. PMID: 23639488. DOI: 10.1016/S0140-6736(13)60140-3.56. Goss P.E., Ingle J.N., Ales-Martin L.J. et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011;364(25):2381–91. PMID: 21639806. DOI: 10.1056/NEJMoa1103507.Goss P.E., Ingle J.N., Ales-Martin L.J. et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011;364(25):2381–91. PMID: 21639806. DOI: 10.1056/NEJMoa1103507.57. Cuzick J., Sestak I., Forbes J.F. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383(9922):1041–8. PMID: 24333009. DOI: 10.1016/S0140-6736(13)62292-8.Cuzick J., Sestak I., Forbes J.F. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383(9922):1041–8. PMID: 24333009. DOI: 10.1016/S0140-6736(13)62292-8.58. Hartmann L.C., Schaid D.J., Woods J.E. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77–84. PMID: 9887158. DOI: 10.1056/NEJM199901143400201.Hartmann L.C., Schaid D.J., Woods J.E. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77–84. PMID: 9887158. DOI: 10.1056/NEJM199901143400201.59. McDonnell S.K., Schaid D.J., Myers J.L. et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19(19):3938–43. PMID: 11579114. DOI: 10.1200/JCO.2001.19.19.3938.McDonnell S.K., Schaid D.J., Myers J.L. et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19(19):3938–43. PMID: 11579114. DOI: 10.1200/JCO.2001.19.19.3938.60. Van Verschuer V.M.T., Maijers M.C., van Deurzen C.H.M., Koppert L.B. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg 2015;4(6):467–75. PMID: 26645001. DOI: 10.3978/j.issn.2227-684X.2015.02.01.Van Verschuer V.M.T., Maijers M.C., van Deurzen C.H.M., Koppert L.B. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg 2015;4(6):467–75. PMID: 26645001. DOI: 10.3978/j.issn.2227-684X.2015.02.01.61. Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCAассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72. [Portnoy S.M., Lyubchenko L.N., Blokhin S.N. et al. Prevention of BRCA-associated breast and ovarian cancer. Literature review and own data. Onkoginekologiya = Gynecologic Oncology 2012;(1):68–72. (In Russ.)].Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCAассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72. [Portnoy S.M., Lyubchenko L.N., Blokhin S.N. et al. Prevention of BRCA-associated breast and ovarian cancer. Literature review and own data. Onkoginekologiya = Gynecologic Oncology 2012;(1):68–72. (In Russ.)].